NCT04834661 is a clinical trial of surgery inside the primary institution in Colorectal Cancer, sponsored by Shanghai Minimally Invasive Surgery Center.

Who is sponsoring NCT04834661?

NCT04834661 is sponsored by Shanghai Minimally Invasive Surgery Center.

What drugs are being tested in NCT04834661?

Interventions in NCT04834661: surgery inside the primary institution, surgery outside the primary institution.

What condition does NCT04834661 study?

NCT04834661 studies Colorectal Cancer, Gastric Cancer.

Is NCT04834661 still recruiting?

NCT04834661 is currently completed. Last updated 18 April 2022.

Last reviewed 2022-04-18 · How we verify

NCT04834661

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Performing Laparoscopic Surgery for Colorectal and Gastric Cancer Outside the Primary Registered Medical Institution

Completed Last updated 18 April 2022

What this trial tests

trial testing surgery inside the primary institution in Colorectal Cancer in 1,130 participants. Completed in 31 December 2021.

Timeline

20 October 2021

Primary endpoint
31 October 2021

31 December 2021

Quick facts

Lead sponsor	Shanghai Minimally Invasive Surgery Center
Status	Completed
Study type	OBSERVATIONAL
Enrollment	1,130
Start date	20 October 2021
Primary completion	31 October 2021
Estimated completion	31 December 2021
Sites	1 location across China

Drugs / interventions tested

surgery inside the primary institution
surgery outside the primary institution

Conditions studied

Colorectal Cancer — all drugs for Colorectal Cancer →
Gastric Cancer — all drugs for Gastric Cancer →

Sponsor

Shanghai Minimally Invasive Surgery Center — full company profile →

Who can join

Adults 18 to 100, any sex, with Colorectal Cancer or Gastric Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study investigates the safety and feasibility of performing laparoscopic surgery for colorectal and gastric cancer inside versus outside the primary registered medical institution under multi-sites practice (MSP) policy. This is a single practitioner, retrospective comparative study. The endpoints are peri-operative outcomes, pathological results, and medical costs.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Safety and feasibility of laparoscopic surgery for colorectal and gastric cancer under the Chinese multi-site practice policy: admittance standards of competence are needed.
Cai Z, Song H, Huang Z, Fingerhut A, et al · · 2022 · cited 4× · PMID 36196254 · DOI 10.1093/gastro/goac046

Verify or expand the search:

Other recruiting trials for Colorectal Cancer

Currently open trials in the same condition.

NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting

Other Shanghai Minimally Invasive Surgery Center trials

Trials by the same sponsor.

NCT07076979 — Development and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Gastric Cancer：MetB · recruiting
NCT07068529 — Development and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Colorectal Cancer：M · recruiting
NCT06746298 — A Prospective Study of Expression Profiling-based Assessment of the Efficacy of Neoadjuvant Therapy for Rectal Cancer · not yet recruiting
NCT04620473 — Anlotinib Hydrochloride Combined With Capeox in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer · Phase 2 · withdrawn
NCT05495048 — Transvaginal NOSES Versus Conventional Laparoscopic Surgery for Right Hemicolectomy · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04834661 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Minimally Invasive Surgery Center
Last refreshed: 18 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04834661.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing